The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | GLP-1 agonists and SGLT-2 inhibitors for treating adults with SCD and nephropathy
Santosh Saraf, MD, University of Illinois Hospital, Chicago, IL, comments on the potential role of GLP-1 agonists and SGLT-2 inhibitors in treating adults with sickle cell disease (SCD), namely those with nephropathy. Dr Saraf notes that these therapies have shown promise in protecting against sickle cell-related kidney damage, with preliminary data showing improved albuminuria, proteinuria, and stabilized kidney function decline. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Yeah, so that’s also along the spectrum of sickle nephropathy, which is what we’re looking at in the animal models. This is using some of the therapies that have become adopted in the general chronic kidney disease literature. And they’ve been really remarkable in diabetic and other forms of nephropathy. And we have some patients with sickle cell disease, we’re seeing increasing diabetes more and more in our patients with sickle cell disease as they’re aging and we’re seeing more of the common kind of problems...
Yeah, so that’s also along the spectrum of sickle nephropathy, which is what we’re looking at in the animal models. This is using some of the therapies that have become adopted in the general chronic kidney disease literature. And they’ve been really remarkable in diabetic and other forms of nephropathy. And we have some patients with sickle cell disease, we’re seeing increasing diabetes more and more in our patients with sickle cell disease as they’re aging and we’re seeing more of the common kind of problems. We wanted to see whether these agents also helped protect against sickle cell-related kidney damage. And what we saw was that albuminuria and proteinuria did remarkably improve and the rate of kidney function decline also stabilized. So it’s a good signal that these agents may also have efficacy in people with sickle cell disease and they need to be further investigated.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
